Expertise in
22
conditions

Dr. David A. Reardon

Hematology Oncology | Hematology | Oncology
450 Brookline Avenue, 
Boston, MA 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
22
conditions
450 Brookline Avenue, 
Boston, MA 

Overview

David Reardon is a Hematologist Oncology specialist and a Hematologist practicing medicine in Boston, Massachusetts.

Dr. Reardon is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, Brain Tumor, and Tissue Biopsy.

Dr. Reardon is board certified in Pediatrics and Pediatric Hematology-Oncology. He is actively involved in clinical research, co-authoring 318 peer reviewed articles and participating in 12 clinical trials. Dr. Reardon is currently accepting new patients.

Specialties

Hematology Oncology
Hematology
Oncology

Licenses

Internal Medicine in MA

Board Certifications

Pediatrics
Pediatric Hematology-Oncology

Fellowships

University of Michigan Health System, 1992

Hospital Affiliations

Brigham And Women's Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Nippon Life
  • INSURANCE PLAN
Oscar
  • EPO
  • HMO
  • PPO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Dana-Farber Cancer Institute, Center for Neuro-Oncology
450 Brookline Avenue, Boston, MA 02115

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma
A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2026
Intervention Type: Biological, Drug, Other
Study Drugs: Montanide ISA 51 VG, Sargramostim, SVN53-67/M57-KLH Peptide Vaccine, Temozolomide
Study Phase: Phase 2
An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progressive/Recurrent Meningioma
An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progressive/Recurrent Meningioma
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Drug, Radiation
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
A Phase II, Open Label, Single Arm Study of Nivolumab for Recurrent or Progressive IDH Mutant Gliomas With Prior Exposure to Alkylating Agents
A Phase II, Open Label, Single Arm Study of Nivolumab for Recurrent or Progressive IDH Mutant Gliomas With Prior Exposure to Alkylating Agents
Enrollment Status: Completed
Publish Date: June 10, 2026
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
Phase Ib Trial of ASP8374 and Cemiplimab in Recurrent Malignant Glioma Patients
Phase Ib Trial of ASP8374 and Cemiplimab in Recurrent Malignant Glioma Patients
Enrollment Status: Completed
Publish Date: October 22, 2025
Intervention Type: Drug
Study Drugs: ASP8374, Cemiplimab
Study Phase: Phase 1
CA209-382 A Randomized Phase 2 Open Label Study of Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in Recurrent Glioblastoma (GBM)
CA209-382 A Randomized Phase 2 Open Label Study of Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in Recurrent Glioblastoma (GBM)
Enrollment Status: Active_not_recruiting
Publish Date: February 28, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Bevacizumab
Study Phase: Phase 2
Phase 1/1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 596 as Monotherapy and in Combination With AMG 404 in Subjects With Glioblastoma or Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)
Phase 1/1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 596 as Monotherapy and in Combination With AMG 404 in Subjects With Glioblastoma or Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)
Enrollment Status: Terminated
Publish Date: October 29, 2024
Intervention Type: Drug
Study Drugs: AMG 596, AMG 404
Study Phase: Phase 1
Phase II Trial of Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
Phase II Trial of Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Radiation
Study Drugs: Pembrolizumab, Bevacizumab
Study Phase: Phase 2
Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma
Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma
Enrollment Status: Completed
Publish Date: March 08, 2024
Intervention Type: Procedure
A Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of BLZ945 as Single Agent and in Combination With PDR001 in Adults Patients With Advanced Solid Tumors
A Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of BLZ945 as Single Agent and in Combination With PDR001 in Adults Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: January 18, 2024
Intervention Type: Drug
Study Drugs: BLZ945, PDR001
Study Phase: Phase 1/Phase 2
A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors (Phase 1b) and in Recurrent or Refractory Non-small Cell Lung Cancer or Hepatocellular Carcinoma (Phase 2)
A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors (Phase 1b) and in Recurrent or Refractory Non-small Cell Lung Cancer or Hepatocellular Carcinoma (Phase 2)
Enrollment Status: Completed
Publish Date: September 09, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

318 Total Publications

Vorasidenib improves response to subsequent chemoradiation in a genetically engineered mouse model of IDH-mutant glioma.
Vorasidenib improves response to subsequent chemoradiation in a genetically engineered mouse model of IDH-mutant glioma.
Journal: Science translational medicine
Published: August 05, 2026
Similar Doctors
Expertise in
18
conditions
Dr. Paul G. Richardson
Hematology Oncology | Oncology | Hematology
Expertise in
18
conditions
Dr. Paul G. Richardson
Hematology Oncology | Oncology | Hematology
Referral may be required
Before you request

Dana-Farber Cancer Institute, Lipper Multiple Myeloma Center

450 Brookline Avenue, 
Boston, MA 
 (0.1 miles away)
617-632-2104
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Paul Richardson is a Hematologist Oncology specialist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Richardson is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Hepatic Venoocclusive Disease with Immunodeficiency, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Graft. Dr. Richardson is board certified in Medical Oncology. Dr. Richardson is currently accepting new patients.

Expertise in
18
conditions
Dr. Steven G. Dubois
Hematology | Oncology
Expertise in
18
conditions
Dr. Steven G. Dubois
Hematology | Oncology
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Steven Dubois is a Hematologist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Dubois is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Ewing Sarcoma, Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, and Osteosarcoma. Dr. Dubois is currently accepting new patients.

Expertise in
31
conditions
Dr. Priscilla A. Merriam
Hematology Oncology | Hematology | Oncology
Expertise in
31
conditions
Dr. Priscilla A. Merriam
Hematology Oncology | Hematology | Oncology
Referral may be required
Before you request

Dana-Farber Cancer Institute, Sarcoma And Bone Cancer Treatment Center

450 Brookline Avenue, 
Boston, MA 
 (0.1 miles away)
617-632-5204
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Priscilla Merriam is a Hematologist Oncology specialist and a Hematologist practicing medicine in Boston, Massachusetts. Dr. Merriam is highly rated in 31 conditions, according to our data. Her clinical expertise encompasses Adult Soft Tissue Sarcoma, Alveolar Soft Part Sarcoma, Liposarcoma, and Epithelioid Sarcoma. Dr. Merriam is board certified in Hematology, Internal Medicine, and Medical Oncology. Dr. Merriam is currently accepting new patients.

Frequently Asked Questions about Dr. David A. Reardon

How do I make an appointment with Dr. David A. Reardon?

You can book an appointment with Dr. David A. Reardon by calling their office at 617-632-2166. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. David A. Reardon a top-rated expert for Glioblastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. David A. Reardon is classified as an Elite expert for Glioblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. David A. Reardon specialize in?

While Dr. David A. Reardon is a Hematology Oncology, they have specific expertise in Glioblastoma, Astrocytoma, and Glioma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. David A. Reardon participate in research or clinical trials?

Yes. Dr. David A. Reardon has published 318 articles and abstracts on conditions like Glioblastoma. You can view a list of Dr. David A. Reardon's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. David A. Reardon accept my insurance?

Dr. David A. Reardon accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 617-632-2166 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Reardon's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 7 Advanced Conditions
View All 15 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile